Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow-derived mesenchymal stem cells.

Kevin C Kemp1, Jill Hows, Craig Donaldson

  • 1Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol, UK.

Leukemia & Lymphoma
|October 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical anesthesia strabismus surgery.

Strabismus·2024
Same author

The Bone Marrow Microenvironment in Immune-Mediated Inflammatory Diseases: Implications for Mesenchymal Stromal Cell-Based Therapies.

Stem cells translational medicine·2023
Same author

Prevalence of Glaucoma Following Paediatric Cataract Surgery in an Australian Tertiary Referral Centre.

Clinical ophthalmology (Auckland, N.Z.)·2023
Same author

An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich's ataxia.

Nature communications·2022
Same author

Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same author

Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522.

Head & neck·2021
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Human mesenchymal stem cells (MSCs) offer promising cellular therapy for hematological malignancies. Clinical studies highlight their potential in supporting patients undergoing chemotherapy and radiotherapy.

Area of Science:

  • Stem Cell Biology
  • Regenerative Medicine
  • Hematology

Background:

  • Human mesenchymal stem cells (MSCs) are crucial for mesenchymal tissue regeneration and support hematopoietic cell development in the bone marrow.
  • Established techniques allow for the isolation and in vitro expansion of human MSCs without altering their phenotype or function.
  • MSCs are recognized for their potential in regenerative medicine, immune modulation, and tissue engineering.

Purpose of the Study:

  • To review the multifaceted aspects of human mesenchymal stem cells (MSCs).
  • To focus on clinical studies investigating the therapeutic potential of MSCs for hematological malignancies.
  • To explore MSCs' role in supporting patients undergoing chemotherapy and radiotherapy.

Main Methods:

  • Review of existing clinical studies and literature.

Related Experiment Videos

  • Analysis of MSC isolation, expansion, and transplantation techniques.
  • Evaluation of MSC therapeutic efficacy in hematological cancer patients.

    • Main Results:

    • Transplanted MSCs have demonstrated feasibility as a cellular therapy.
    • MSCs show significant potential in treating patients with hematological malignancies.
    • The review synthesizes findings from various clinical trials regarding MSC applications.

    Conclusions:

    • Mesenchymal stem cells represent a promising avenue for cellular therapy in hematological malignancies.
    • Further clinical investigation is warranted to fully elucidate the benefits of MSCs in cancer treatment.
    • MSCs hold considerable promise for improving patient outcomes in oncology.